Document Detail


Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis.
MedLine Citation:
PMID:  16773275     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A recent meta-analysis of the Cholesterol Treatment Trialists' (CTT) Collaboration comes to the clear conclusion that a reduction in LDL-C using statins of 1 mmol/l (39 mg/dl) leads to a decrease in overall mortality by 12%, in coronary mortality by 19% and in the incidence of strokes by 17%, independent of the LDL-C level prior to the start of treatment. We conducted a systematic review retrieving 18 studies with a total of 116,343 [corrected] participants. Differences in average LDL-C reductions between the intervention and control groups during the follow-up and relative risks according to different clinical endpoints were extracted from the original publications. Metaregression analyses showed that reduction in LDL-C accounted for more than 75% of the variance in risk reductions for overall mortality and cardiovascular endpoints. On the basis of our estimates, a reduction in LDL-C of 1 mmol/l (39 mg/dl) leads to reductions in overall mortality, coronary mortality, incidence of non-fatal myocardial infarction, the combination of coronary mortality and non-fatal myocardial infarction, stroke and any vascular event by 15% (95% CI: 11-20%), 24% (95% CI: 20-28%), 27% (95% CI: 20-32%), 25% (95% CI: 22-29%), 24% (18-29%) and 22% (95% CI: 19-26%), respectively. We conclude that the extent to which statins lower LDL-C is strongly related to the improvement of clinical outcomes achieved by this class of drugs.
Authors:
Bernd Genser; Winfried März
Related Documents :
12735555 - Radial artery use is safe in patients with moderate to severe left ventricular dysfunct...
10368115 - Comparing ami mortality among hospitals in patients 65 years of age and older: evaluati...
10803005 - Complications from cardiac catheterization: analysis of a military database.
12695455 - A single serum glucose measurement predicts adverse outcomes across the whole range of ...
10587695 - Analytic and clinical evaluation of the abbott axsym cardiac troponin i assay.
2969235 - Lipoprotein lp(a). a risk factor for myocardial infarction.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review     Date:  2006-06-20
Journal Detail:
Title:  Clinical research in cardiology : official journal of the German Cardiac Society     Volume:  95     ISSN:  1861-0684     ISO Abbreviation:  -     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-07-26     Completed Date:  2007-04-03     Revised Date:  2007-10-26    
Medline Journal Info:
Nlm Unique ID:  101264123     Medline TA:  Clin Res Cardiol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  393-404     Citation Subset:  IM    
Affiliation:
BGStats Consulting, Hochstrasse 7, 8071, Graz, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiovascular Diseases* / blood,  drug therapy,  epidemiology
Cholesterol, LDL / blood*,  drug effects
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Incidence
Prognosis
Risk Factors
Survival Rate
Chemical
Reg. No./Substance:
0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors
Comments/Corrections
Erratum In:
Clin Res Cardiol. 2007 Jul;96(7):526

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Follow-up of a large population of asymptomatic/oligosymptomatic hyperckemic subjects.
Next Document:  Evaluation of morphological and molecular variation in Plantago asiatica var. densiuscula, with spec...